Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 253

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 253
---
, by an       
 additional 20,000 shares each. At a special meeting of stockholders on November 11, 2024, the stockholders approved an increase in      
 the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant to incentive       
 stock options, by an additional 208,454 shares each. As of January 8, 2025, no awards have been granted under the 2024 ESPP. No new     
 awards may be granted under the 2016 Plan, but all outstanding awards under the 2016 Plan continue to be governed by their existing     
 terms. The 2024 Plan has an evergreen provision that allows for an annual increase in the number of shares available for issuance       
 under the 2024 Plan to be added on the first day of January, starting with January 1, 2025, in an amount equal to the lesser of (i)     
 5% of the fully diluted shares of our common stock on the immediately preceding December 31 or (ii) such number of shares as determined 
 by our board in each case subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.    
 On January 1, 2025, the number of shares reserved under the 2024 Plan was increased by 5% of the fully diluted shares of our common     
 stock on the immediately preceding December 31, or 189,701 shares. The 2024 ESPP has an evergreen provision that allows for an annual   
 increase in the number of shares available for issuance under the 2024 ESPP to be added on the first day of each January, starting      
 with January 1, 2024, by the lesser of (i) 10,198 shares of our common stock, (ii) 1% of the fully diluted shares of common stock       
 on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by our board. The number of      
 shares reserved under the 2023 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our       
 capitalization. As of January 8, 2025, the board of directors have granted an aggregate of 61,080 option awards under the 2024 Plan,    
 leaving 408,801 shares reserved for future issuance under the 2024 Plan.                                                                |

162 CERTAIN RELATIONSHIPS AND